The trial marks “a significant milestone in the battle against addiction,” the biotech company declared.
Clearmind Medicine recently reported positive results in a trial evaluating the efficacy of its psychedelic treatment targeting cocaine addiction.
The trial, which involved its psychedelic molecule, MEAI, marks “a significant milestone in the battle against addiction,” the biotech company declared.
Professor Gal Yadid and his team from the Gonda Multidisciplinary Brain Research Center at Bar Ilan University in Israel led the trial following a previous experiment that showed a marked decrease in cocaine-induced craving among rats treated with MEAI, according to Clearmind.
“These results, previously announced, offer a beacon of hope, demonstrating the potential efficacy of MEAI in reducing cocaine-related conditions,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. “Our unique psychedelic compound has shown remarkable results in pre-clinical trials for cocaine addiction.
“These promising results from our MEAI-based treatment offer a potential paradigm shift in how we approach the complex challenge of cocaine addiction, an addiction for which no dedicated treatment has yet been developed.”
With millions of people affected by cocaine addiction, “the successful application of MEAI could revolutionize treatment protocols and offer new hope to those trapped in the cycle of addiction,” Clearmind added in a news release.
MEAI is short for 5-Methoxy-2-aminoindane, a novel psychoactive aminoindane derivative. Clearmind is researching the potential efficacy of MEAI for various addictions, obesity and metabolic disorders and depression.